You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Protected research time required for oncologists – Cancer Trials Ireland

By Dermot - 05th Jul 2017 | 1 views

Speaking following the launch of the National Cancer Strategy 2017-2026, Prof Bryan Hennessy, Clinical Lead of Cancer Trials Ireland, and Consultant Oncologist at Beaumont Hospital in Dublin, said the document’s implementation “could take us significantly closer to finding successful treatments for all types of cancer”.

He commented: “It acknowledges that cancer trials should be a core activity of cancer centres and recommends that they should be fully integrated into cancer care delivery. These actions will take cancer research to a new level. Cancer trials will not be outliers on the periphery, but central to the treatment options available to people with cancer.

 “The target to double the number of people with cancer who can access cancer trials, from the current 3 per cent to 6 per cent will not only save the HSE millions of euro in drug costs (currently €6.5 million annually) it will provide more patients with access to promising new treatments that would otherwise not be available.

“We are very pleased that the strategy recommends establishing a National Cancer Research Group, which can maximise the impact of Ireland’s collective investment in cancer research. We look forward to working with our colleagues at the National Cancer Control Programme (NCCP) to get the Group up and running without delay.”

There are almost 100 open cancer trials recruiting patients in Ireland.  A further 50 trials are under way but have completed their recruitment phase.  There are up to 6,000 patients involved in all of these trials.

Meanwhile, the Irish Pharmaceutical Healthcare Association (IPHA) has said a “timely reimbursement system” must be in place if the strategy is to deliver on its objectives.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]